HUE052407T2 - Optimalizált RPE65 promoter- és kódoló szekvenciák - Google Patents
Optimalizált RPE65 promoter- és kódoló szekvenciákInfo
- Publication number
- HUE052407T2 HUE052407T2 HUE16703850A HUE16703850A HUE052407T2 HU E052407 T2 HUE052407 T2 HU E052407T2 HU E16703850 A HUE16703850 A HU E16703850A HU E16703850 A HUE16703850 A HU E16703850A HU E052407 T2 HUE052407 T2 HU E052407T2
- Authority
- HU
- Hungary
- Prior art keywords
- coding sequences
- rpe65 promoter
- optimized
- optimized rpe65
- promoter
- Prior art date
Links
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 title 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01064—Retinoid isomerohydrolase (3.1.1.64)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Eye Examination Apparatus (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1502137.1A GB201502137D0 (en) | 2015-02-09 | 2015-02-09 | Treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE052407T2 true HUE052407T2 (hu) | 2021-04-28 |
Family
ID=52746363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16703850A HUE052407T2 (hu) | 2015-02-09 | 2016-02-08 | Optimalizált RPE65 promoter- és kódoló szekvenciák |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10568973B2 (enExample) |
| EP (2) | EP3256169B1 (enExample) |
| JP (1) | JP6963503B2 (enExample) |
| CN (1) | CN107429252B (enExample) |
| AU (1) | AU2016217654B2 (enExample) |
| BR (1) | BR112017017060A2 (enExample) |
| CA (1) | CA2975850C (enExample) |
| CY (1) | CY1123947T1 (enExample) |
| DK (1) | DK3256169T3 (enExample) |
| ES (1) | ES2830030T3 (enExample) |
| GB (1) | GB201502137D0 (enExample) |
| HR (1) | HRP20201831T1 (enExample) |
| HU (1) | HUE052407T2 (enExample) |
| IL (2) | IL287142B2 (enExample) |
| LT (1) | LT3256169T (enExample) |
| MX (2) | MX383316B (enExample) |
| PH (1) | PH12017501430A1 (enExample) |
| PL (1) | PL3256169T3 (enExample) |
| PT (1) | PT3256169T (enExample) |
| RS (1) | RS61079B1 (enExample) |
| SG (1) | SG11201706520UA (enExample) |
| SI (1) | SI3256169T1 (enExample) |
| SM (1) | SMT202000655T1 (enExample) |
| WO (1) | WO2016128722A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| MX2018013205A (es) * | 2016-04-28 | 2019-06-24 | Spark Therapeutics Inc | Ensayo de potencia relativa para un vector viral que codifica isomero hidrolasas. |
| WO2019106035A1 (en) * | 2017-11-30 | 2019-06-06 | Friedrich Miescher Institute For Biomedical Research | Synpiii, a promoter for the specific expression of genes in retinal pigment epithelium |
| CN111118017B (zh) * | 2018-11-01 | 2023-10-03 | 上海朗昇生物科技有限公司 | 治疗Leber先天性黑蒙症的载体及其应用 |
| PT3850089T (pt) | 2019-02-04 | 2024-01-24 | Freeline Therapeutics Ltd | Polinucleótidos |
| GB202002202D0 (en) | 2020-02-18 | 2020-04-01 | Ucl Business Plc | Gene therapy |
| CN113952471A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| EP4185335A1 (en) * | 2020-07-21 | 2023-05-31 | Frontera Therapeutics, Inc. | Compositions and methods for the treatment of ocular diseases |
| CN111826378B (zh) * | 2020-08-05 | 2022-05-27 | 武汉纽福斯生物科技有限公司 | 一种编码人受体酪氨酸激酶Mer的核苷酸序列及其应用 |
| CN112522292B (zh) * | 2020-10-29 | 2023-05-02 | 南京启真基因工程有限公司 | 一种用于构建先天性黑蒙症克隆猪核供体细胞的CRISPR/Cas9系统及其应用 |
| EP4399314A4 (en) * | 2021-09-06 | 2025-09-10 | Huidagene Therapeutics Singapore Pte Ltd | TREATMENT OF EYE DISEASES AND DISORDERS ASSOCIATED WITH RPE65 |
| CN120882416A (zh) * | 2023-01-05 | 2025-10-31 | 欧普斯遗传学股份有限公司 | 用于眼部疾病的基因疗法 |
| CN117018235A (zh) * | 2023-06-20 | 2023-11-10 | 浙江大学 | 一种可用于活体的可视化神经环路的方法及工具病毒载体 |
| CN116898991A (zh) * | 2023-06-20 | 2023-10-20 | 浙江大学 | 一种可用于活体的可视化的神经活动状态评估方法及工具病毒载体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080064061A1 (en) | 2004-08-06 | 2008-03-13 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Yeast Promoter |
| US7740836B2 (en) | 2006-05-03 | 2010-06-22 | Fondazione Telethon | Methods and compositions for recovering or improving visual function |
| US20100081707A1 (en) * | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| LT3418300T (lt) | 2011-07-18 | 2021-01-11 | Institute For Research In Biomedicine | Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas |
| US9163259B2 (en) * | 2012-05-04 | 2015-10-20 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| GB201502137D0 (en) * | 2015-02-09 | 2015-03-25 | Ucl Business Plc | Treatment |
| GB202002073D0 (en) * | 2020-02-14 | 2020-04-01 | Ucl Business Ltd | Horizontal cells |
| GB202002202D0 (en) * | 2020-02-18 | 2020-04-01 | Ucl Business Plc | Gene therapy |
-
2015
- 2015-02-09 GB GBGB1502137.1A patent/GB201502137D0/en not_active Ceased
-
2016
- 2016-02-08 DK DK16703850.4T patent/DK3256169T3/da active
- 2016-02-08 RS RS20201400A patent/RS61079B1/sr unknown
- 2016-02-08 SI SI201630984T patent/SI3256169T1/sl unknown
- 2016-02-08 CA CA2975850A patent/CA2975850C/en active Active
- 2016-02-08 CN CN201680020425.6A patent/CN107429252B/zh active Active
- 2016-02-08 IL IL287142A patent/IL287142B2/en unknown
- 2016-02-08 HU HUE16703850A patent/HUE052407T2/hu unknown
- 2016-02-08 LT LTEP16703850.4T patent/LT3256169T/lt unknown
- 2016-02-08 SG SG11201706520UA patent/SG11201706520UA/en unknown
- 2016-02-08 WO PCT/GB2016/050289 patent/WO2016128722A1/en not_active Ceased
- 2016-02-08 PT PT167038504T patent/PT3256169T/pt unknown
- 2016-02-08 BR BR112017017060-4A patent/BR112017017060A2/pt active Search and Examination
- 2016-02-08 JP JP2017541749A patent/JP6963503B2/ja active Active
- 2016-02-08 ES ES16703850T patent/ES2830030T3/es active Active
- 2016-02-08 SM SM20200655T patent/SMT202000655T1/it unknown
- 2016-02-08 EP EP16703850.4A patent/EP3256169B1/en active Active
- 2016-02-08 AU AU2016217654A patent/AU2016217654B2/en active Active
- 2016-02-08 PL PL16703850T patent/PL3256169T3/pl unknown
- 2016-02-08 EP EP20193488.2A patent/EP3769790A1/en active Pending
- 2016-02-08 MX MX2017010292A patent/MX383316B/es unknown
- 2016-02-08 HR HRP20201831TT patent/HRP20201831T1/hr unknown
- 2016-02-08 US US15/549,549 patent/US10568973B2/en active Active
-
2017
- 2017-08-08 IL IL253915A patent/IL253915B/en unknown
- 2017-08-09 PH PH12017501430A patent/PH12017501430A1/en unknown
- 2017-08-09 MX MX2021006762A patent/MX2021006762A/es unknown
-
2020
- 2020-02-20 US US16/796,439 patent/US11969478B2/en active Active
- 2020-11-26 CY CY20201101129T patent/CY1123947T1/el unknown
-
2024
- 2024-04-25 US US18/646,126 patent/US20240293580A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287142A (en) | Optimized rpe65 promoter and coding sequences | |
| PL3250692T3 (pl) | Promotor i jego zastosowania | |
| HUE057965T2 (hu) | Új promóter és alkalmazása | |
| EP3311570C0 (en) | INTRA PREDICTION AND CODING IN INTRA PREDICTION MODE | |
| GB2539546B (en) | Enhanced quick response codes | |
| DK3872085T3 (da) | Stam-virussekvenser og anvendelser heraf | |
| GB2525430B (en) | Error-correction encoding and decoding | |
| DK3332005T3 (da) | Promotorvarianter | |
| EP3344595A4 (en) | BLASTING AGENT | |
| EP4365895C0 (en) | DECODING AT REDUCED SCALE | |
| BR112017026299A2 (pt) | conjunto e embarcação | |
| GB2544586B (en) | Track-dependent decoding | |
| GB2543926B (en) | Repair-optimal parity code | |
| PL3279327T3 (pl) | Nowy promotor i jego zastosowanie | |
| DK3319625T3 (da) | Immunogene præ-procalcitoninpeptider | |
| ES1140635Y (es) | Abrasivo optimizado | |
| ES1141333Y (es) | Protesis atipica bucal | |
| FI11161U1 (fi) | Kynnys | |
| AU361930S (en) | Peg | |
| GB201517506D0 (en) | Pumping assembly | |
| GB201517504D0 (en) | Pumping assembly | |
| GB201513676D0 (en) | Inflatables / deflatables | |
| UA31959S (uk) | Балон | |
| FI10921U1 (fi) | Kynnys | |
| GB201403765D0 (en) | ORCTL3 Sequences and their uses |